Karthik Achari Builds Independence Into PepMD’s Business Decisions

An invoice can put a business principle under pressure. For Karthik Achari, building PepMD has involved deciding which financial relationships fit an organization seeking to establish standards in peptide medicine. Peptides are short chains of amino acids that can stimulate hormone activity, immune defense, tissue repair and growth, digestion, and more.

He says he declined some opportunities for early revenue because of the questions they could raise about the company’s independence later. “Independence sounds like a value until it’s an invoice that you’re declining,” Achari notes.

PepMD describes itself as a private standards body developing trust infrastructure and credentialing within the industry. In other words, he wants patients to understand a provider’s qualifications.

Achari sees the source of PepMD’s revenue as one component of establishing credibility. A commercial arrangement enters the discussion through the expectations attached to it, as well as the money it could bring. 

Revenue arrives with a relationship

Referral relationships and commercial partnerships offered possible routes to growth during PepMD’s development, according to Achari. Assessing them involved looking ahead to how the organization’s judgment might be viewed once those arrangements were in place.

His concern centers on objectivity, he says. An organization working on standards may eventually have to explain how it reached a decision. A financial relationship could become part of that explanation, particularly where another party has an interest in the outcome. 

Achari believes independence belongs in the business model itself. Reviewing a potential source of revenue gives him an early opportunity to examine whether the relationship supports the role PepMD intends to occupy.

Declining an opportunity also leaves work to do. The organization still needs a way to support its development, and its founder still faces decisions about growth. Achari wants arrangements that can withstand scrutiny as the work develops.

Financial choices made during those early stages may remain relevant when a larger audience begins asking how the organization operates. He wants the reasoning behind them to hold up if those questions arise.

What happens after a decision is made matters

Achari’s experience spans precision diagnostics, medical supply distribution, and pharmaceutical manufacturing. Across those businesses, he says he came to pay closer attention to what happens after a decision has been made.

An email can be revised during the next exchange, and a proposal may change as a conversation develops. Those choices give him room to act, see the response, and make another adjustment.

Company identity carries a longer history. The way an organization introduces itself may become familiar to partners before its founder has had much time to reconsider it. A partnership can also establish expectations that continue through subsequent work.

“I’m fast where speed is cheap, and I’m slow where mistakes are hard to come back from,” he explains.

Achari uses reversibility to decide how much time a choice deserves. Where a correction is straightforward, he is comfortable moving quickly. Decisions involving reputation or organizational responsibilities receive more attention.

An opportunity available today can create pressure to act, with consequences extending through years of operation. He weighs the immediate opening alongside the work that may follow it.

At PepMD, that thinking brings the organization’s intended role into discussions about growth. A proposed arrangement has to be considered in relation to the standards work the company plans to undertake. 

The work behind a credential

Achari’s interests increasingly extend to the information surrounding healthcare practices. Credential verification is one part of that work. He envisions patients having an accessible way to understand a provider’s qualifications.

A designation carries meaning through the information associated with it. His plans bring attention to how credentials are described and checked, with the aim of making that information easier for patients to understand when assessing a provider. 

PepMD’s stated development priorities also include outcome registries and adverse-event tracking. Achari sees these as smaller components of a larger effort to support accountability within peptide medicine.

Qualifications relate to the provider’s background. Outcomes concern what follows care, and adverse-event tracking relates to reported problems. He is interested in how those records could contribute to a more understandable account of practice. 

The organization’s plans remain focused on developing that infrastructure. Achari connects the standards themselves with the process of how records could be collected and interpreted. 

A credential or quality designation would carry an explanation of why it was awarded. That connection between a designation and its supporting information is part of the role he wants PepMD to develop. 

Planning for a larger field

Achari is also considering what an emerging category may need as participation expands. His interest in standards reaches into the questions that could arise as more providers and patients become involved.

He wants recognizable processes for examining qualifications and accountability. As the field develops, those processes would give the organization a basis for explaining its work to a broader audience.

Quality recognition is another area he identifies. Achari’s interest is in communicating how recognition is awarded to give people an explanation they can examine alongside the designation.

That ambition returns him to independence. A recognition system would operate through relationships established by the organization, making the terms relevant during its development.

For Achari, the business decisions and the intended standards work remain closely connected. The organization’s sources of support may become part of how others assess its judgment later. 

Success through the patient’s view

Achari says his long-term ambition is to develop a field where patients can understand provider qualifications and where standards have an established place. He hopes the systems supporting accountability become familiar parts of how peptide medicine operates. 

His measure of success concerns the experience of finding and understanding that information. A patient encountering a credential would have a way to establish what it represents, with recognizable standards providing further orientation.

PepMD’s development now involves decisions that may shape that experience years ahead. Achari remains focused on its standards and credentialing work, with financing choices made alongside those plans.

An arrangement accepted today may become part of how the organization explains itself to a patient or provider later. He wants the decisions made during development to support the role PepMD is working toward. 

This article is for informational purposes only and does not substitute for professional medical advice. If you are seeking medical advice, diagnosis or treatment, please consult a medical professional or healthcare provider.

Entrepreneur Media was not involved in the creation of this content.